Results 201 to 210 of about 5,796 (217)

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

Journal of Pediatrics, 2003
exaly  

Palivizumab Treatment of Respiratory Syncytial Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Infectious Diseases, 2007
Anne Bergeron
exaly  

Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience

Journal of Pediatrics, 2017
Pablo J Sánchez, Octavio Ramilo, Asuncion Mejias   +2 more
exaly  

Palivizumab Prophylaxis and Recurrent Wheezing

American Journal of Respiratory and Critical Care Medicine, 2018
openaire   +2 more sources

Palivizumab Prophylaxis, Respiratory Syncytial Virus, and Subsequent Recurrent Wheezing

Journal of Pediatrics, 2007
exaly  

Palivizumab prophylaxis in preterm infants

The Lancet Respiratory Medicine, 2017
openaire   +2 more sources

Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody, in Adults and Children

Antimicrobial Agents and Chemotherapy, 2012
exaly  

Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review

Infectious Diseases and Therapy, 2014
exaly  

PALIPERIDONE PALIVIZUMAB

2014
openaire   +1 more source

Life Years Gained From Palivizumab

Pediatric Infectious Disease Journal, 2012
openaire   +2 more sources